These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21781652)

  • 1. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype-Guided Hydralazine Therapy.
    Collins KS; Raviele ALJ; Elchynski AL; Woodcock AM; Zhao Y; Cooper-DeHoff RM; Eadon MT
    Am J Nephrol; 2020; 51(10):764-776. PubMed ID: 32927458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.
    Han LW; Ryu RJ; Cusumano M; Easterling TR; Phillips BR; Risler LJ; Shen DD; Hebert MF
    J Clin Pharmacol; 2019 Dec; 59(12):1678-1689. PubMed ID: 31257615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative bioavailability of immediate- and sustained-release hydralazine formulations.
    Ludden TM; Rotenberg KS; Ludden LK; Shepherd AM; Woodworth JR
    J Pharm Sci; 1988 Dec; 77(12):1026-32. PubMed ID: 3244106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers.
    Reece PA; Stafford I; Prager RH; Walker GJ; Zacest R
    J Pharm Sci; 1985 Feb; 74(2):193-6. PubMed ID: 3989691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
    Rowell NP; Clark K
    Radiother Oncol; 1990 Aug; 18(4):293-8. PubMed ID: 2244017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
    Strandberg I; Boman G; Hassler L; Sjöqvist F
    Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydralazine therapy and acetylator phenotype.
    Iisalo E; Laine T; Lehtonen A; Sellman R
    Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):119-24. PubMed ID: 429082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
    Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
    Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.